Discovery of novel, high potent, ABC type PTP1B inhibitors with TCPTP selectivity and cellular activity

Peihong Liu1, Yongli Du1, Lianhua Song1

  • 1School of Chemistry and Pharmaceutical Engineering, Qilu University of Technology, 3501 Daxue Road, Jinan 250353, China.

Insights

Researchers developed novel methyl salicylate derivatives as potent inhibitors of protein tyrosine phosphatase 1B (PTP1B). Compound P6 shows high efficacy and selectivity, offering potential for type 2 diabetes and obesity treatments.

Area of Science:

  • Biochemistry
  • Pharmacology
  • Medicinal Chemistry

Background:

  • Protein tyrosine phosphatase 1B (PTP1B) is a key negative regulator of insulin and leptin signaling pathways.
  • Dysregulation of PTP1B is implicated in type 2 diabetes mellitus (T2DM) and obesity.
  • Developing selective PTP1B inhibitors is crucial for therapeutic intervention.

Purpose of the Study:

  • To discover and optimize novel methyl salicylate derivatives as potent and selective PTP1B inhibitors.
  • To evaluate the inhibitory activity and selectivity of these compounds against PTP1B.
  • To assess the cellular effects of the lead compound on insulin signaling and glucose uptake.

Main Methods:

  • Synthesis of a series of methyl salicylate derivatives (P1-P7) designed as ABC-type PTP1B inhibitors.
  • In vitro enzymatic assays to determine inhibitory concentrations (IC50) and selectivity against PTP1B and T-cell PTPase (TCPTP).
  • Cellular assays to measure insulin receptor β (IRβ) phosphorylation and insulin-stimulated glucose uptake.

Main Results:

  • Compound P6 demonstrated potent inhibition of PTP1B with an IC50 of 50 nM.
  • Compound P6 exhibited significant selectivity, showing 15-fold higher potency against PTP1B compared to TCPTP.
  • In cellular studies, compound P6 enhanced insulin-mediated IRβ phosphorylation and insulin-stimulated glucose uptake.

Conclusions:

  • Methyl salicylate derivatives represent a promising class of PTP1B inhibitors.
  • Compound P6 is a highly potent and selective PTP1B inhibitor with potential therapeutic applications for T2DM and obesity.
  • Compound P6's ability to modulate insulin signaling pathways warrants further investigation for metabolic disease treatment.

Related Concept Videos

ABC Transporters: Importer01:27

ABC Transporters: Importer

ATP-binding cassette or ABC transporters are a class of ATP-driven pumps that hydrolyze ATP to move solutes across the membrane. They can be grouped into importers and exporters. While exporters are present in all domains of life, importers exist only in bacteria and some plants.
In bacteria, based on the number of transmembrane helices and the chemical nature of their substrates, the ABC importers can be divided into three types:
3.7K
Inhibition of Cdk Activity02:34

Inhibition of Cdk Activity

The orderly progression of the cell cycle depends on the activation of Cdk protein by binding to its cyclin partner. However, the cell cycle must be restricted when undergoing abnormal changes. Most cancers correlate to the deregulated cell cycle, and since Cdks are a central component of the cell cycle, Cdk inhibitors are extensively studied to develop anticancer agents. For instance, cyclin D associates with several Cdks, such as Cdk 4/6, to form an active complex. The cyclin D-Cdk4/6 complex...
6.2K
ABC Transporters: Exporter01:31

ABC Transporters: Exporter

ATP-binding cassette or ABC transporter is the largest superfamily of integral membrane proteins. The transporters have transmembrane-binding domains (TMDs) and nucleotide-binding domains (NBDs). The TMDs are specific to their substrates, whereas the NBDs are similar to engines that complete ATP hydrolysis to complete the substrate transport. They can be full transporters consisting of two TMDs and NBDs, half transporters with one TMD and NBD, while some encoded with a single TMD or NBD are...
7.1K